Basic pharmacologic approach to immunosuppressive therapy for autoimmune blistering diseases

Dermatologic Therapy

Volumn 15, Issue 4, 2002, Pages 293-297

  Nousari, H Carlos ^a   Anhalt, Grant J ^a  

^a JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Bullous pemphigoid; Immunosuppressive drugs; Pathophysiology; Pemphigus; Therapy

Indexed keywords

ALKYLATING AGENT; AUTOANTIBODY; AZATHIOPRINE; CHLORAMBUCIL; CYCLOPHOSPHAMIDE; CYCLOSPORIN A; DAPSONE; DESMOGLEIN; IMMUNOMODULATING AGENT; IMMUNOSUPPRESSIVE AGENT; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; NICOTINAMIDE; PREDNISONE; STEROID; TETRACYCLINE;

ANTIBODY PRODUCTION; AUTOIMMUNE DISEASE; BLISTER; BULLOUS SKIN DISEASE; DISEASE MODEL; DRUG EFFICACY; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; INFECTION; INFLAMMATION; MORBIDITY; OSTEOPENIA; PATHOPHYSIOLOGY; PEMPHIGOID; PEMPHIGUS; PEMPHIGUS VULGARIS; PLASMAPHERESIS; REVIEW; STEROID THERAPY;

EID: 0036969681     PISSN: 13960296     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1529-8019.2002.01537.x     Document Type: Review

References (15)

1. Anhalt GJ, Labib RS, Vorhees JJ, et al. Induction of pemphigus in neonatal mice by passive transfer of IgG from patients with the disease. N Engl J Med 1982: 306: 1189-1196.
2. Amagai M, Klaus-Kovtum V, Stanley JR. Autoantibodies against a novel epithelial cadherin in pemphigus vulgaris. Cell 1991: 67: 869-877.
3. Ishii K, Amagai M, Hall RP, et al. Characterization of autoantibodies in pemphigus using antigen-specific ELISAs with baculovirus expressed recombinant proteins. J Immunol 1997: 159: 2010-2017.
4. Koch PJ, Mahoney MG, Ishikawa H, et al. Targeted disruption of the pemphigus vulgaris antigen (desmoglein 3) gene in mice causes loss of keratinocyte cell adhesion with a phenotype similar to pemphigus vulgaris. J Cell Biol 1997: 137: 1091-1102.
5. Ding X, Aoki V, Mascaro JM, et al. Mucosal and mucocutaneous (generalized) pemphigus vulgaris show distinct autoantibody profiles. J Invest Dermatol 1997: 109: 592-596.
6. Amagai T, Hashimoto T, Shimizu N, Nishikawa T. Absorption of pathogenic autoantibodies by the extracellular domain of pemphigus vulgaris antigen (Dsg3) produced by baculovirus. J Clin Invest 1994: 94: 59-67.
7. Anhalt GJ, Till GO, Diaz LA, et al. Defining the role of complement in experimental pemphigus in mice. J Immunol 1986: 137: 2835-2840.
8. Anhalt GJ, Patel HP, Labib RS, et al. Dexamethasone inhibits plasminogen activator activity in experimental pemphigus in vivo but does not block acantholysis. J Immunol 1986: 136: 113-117.
9. Anhalt GJ. Bullous diseases. In: Rakel RE, ed. Conn's current therapy. WB Saunders, Philadelphia, 1995: 766-772.
10. Zillikens D, Mascaro JM, Rose PA, et al. A highly sensitive Enzyme-linked immunosorbent assay for the detection of circulating anti-BP180 autoantibodies in patients with bullous pemphigoid. J Invest Dermatol 1997: 109: 679-683.
11. Muller S, Klaus-Kovtun V, Stanley JR. A 230 kD basic protein is the major bullous pemphigoid antigen. J Invest Dermatol 1989: 92: 33-38.
12. Guidice GJ, Emery DJ, Diaz LA. Cloning and primary structural analysis of the bullous pemphigoid autoantigen BP180. J Invest Dermatol 1992: 99: 243-250.
13. Liu Z, Guidice GJ, Zhou X, et al. A major role for neuthrophils in experimental bullous pemphigoid. J Clin Invest 1997: 100: 1256-1263.
14. Liu Z, Giudice GJ, Swartz SJ, et al. The role of complement in experimental bullous pemphigoid. J Clin Invest 1995: 95: 1539-1544.
15. Stahle-Backdahl M, Inoue M, Guidice GJ, Parks W. 92-kD gelatinase is produced by eosinophils at the site of blister formation of bullous pemphigoid and autoantigen. J Clin Invest 1994: 93: 2022-2030.